270 related articles for article (PubMed ID: 31940473)
1. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
3. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
4. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.
Paolucci S; Campanini G; Cassaniti I; Tebaldi A; Novazzi F; Fratini A; Meini A; Girelli F; Palumbo L; Plebani A; Baldanti F
BMC Infect Dis; 2021 Sep; 21(1):994. PubMed ID: 34556034
[TBL] [Abstract][Full Text] [Related]
6. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
7. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
Drouot E; Piret J; Boivin G
Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
[TBL] [Abstract][Full Text] [Related]
8. Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of
Jackson JW; Hancock TJ; Dogra P; Patel R; Arav-Boger R; Williams AD; Kennel SJ; Wall JS; Sparer TE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760613
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood.
Baldanti F; Simoncini L; Sarasini A; Zavattoni M; Grossi P; Revello MG; Gerna G
Transplantation; 1998 Aug; 66(3):324-9. PubMed ID: 9721800
[TBL] [Abstract][Full Text] [Related]
11. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
12. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
Tenney DJ; Yamanaka G; Voss SM; Cianci CW; Tuomari AV; Sheaffer AK; Alam M; Colonno RJ
Antimicrob Agents Chemother; 1997 Dec; 41(12):2680-5. PubMed ID: 9420038
[TBL] [Abstract][Full Text] [Related]
13. Filociclovir Is a Potent
Toth K; Hussein ITM; Tollefson AE; Ying B; Spencer JF; Eagar J; James SH; Prichard MN; Wold WSM; Bowlin TL
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816736
[TBL] [Abstract][Full Text] [Related]
14. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
Bounaadja L; Piret J; Goyette N; Boivin G
J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
[TBL] [Abstract][Full Text] [Related]
16. Small Molecules-Prospective Novel HCMV Inhibitors.
Bogner E; Egorova A; Makarov V
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809292
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
18. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
19. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro.
Yamada R; Suda H; Sadanari H; Matsubara K; Tuchida Y; Murayama T
Antiviral Res; 2016 Jan; 125():79-83. PubMed ID: 26640224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]